Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Ruta D Rao"'
Autor:
Mudit Chowdhary, MD, Neilayan Sen, MD, Akansha Chowdhary, MD, Lydia Usha, MD, Melody A. Cobleigh, MD, Dian Wang, MD, PhD, Kirtesh R. Patel, MD, Parul N. Barry, MD, Ruta D. Rao, MD
Publikováno v:
Advances in Radiation Oncology, Vol 4, Iss 3, Pp 453-457 (2019)
Purpose: Palbociclib is a selective cyclin-dependent kinase 4/6 inhibitor approved for metastatic ER+/HER2- breast cancer. Preclinical evidence suggests a possible synergistic effect of palbociclib when combined with radiation therapy (RT); however,
Externí odkaz:
https://doaj.org/article/687ff5b0e4af43e08117257c105f29a6
Autor:
Margaret C. Schermerhorn, Miles W. Grunvald, Cristina M. O’Donoghue, Ruta D. Rao, Adan Z. Becerra
Publikováno v:
Annals of Surgical Oncology. 29:7652-7658
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::645249c15fd3bc8d6ed2cc55e286375a
https://doi.org/10.1245/s10434-022-12001-5
https://doi.org/10.1245/s10434-022-12001-5
Autor:
Margaret C. Schermerhorn, Miles W. Grunvald, Cristina M. O’Donoghue, Ruta D. Rao, Adan Z. Becerra
Publikováno v:
Annals of surgical oncology. 29(12)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58fbe7746e37e6604a02706e06856275
https://pubmed.ncbi.nlm.nih.gov/36036842
https://pubmed.ncbi.nlm.nih.gov/36036842
Autor:
Margaret C, Schermerhorn, Miles W, Grunvald, Cristina M, O'Donoghue, Ruta D, Rao, Adan Z, Becerra
Publikováno v:
Annals of surgical oncology. 29(12)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b568b736f344066b6d92cdd714292e41
https://pubmed.ncbi.nlm.nih.gov/35751007
https://pubmed.ncbi.nlm.nih.gov/35751007
Publikováno v:
Asian Pacific Journal of Cancer Prevention : APJCP
Background: Breast cancer has a rich history of research over the past 75 years. Many studies have had disruptive influences on the field itself. Our study employs a new, validated measurement to determine the most disruptive publications within the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6e952b7a16780e108433f710ddafc01
http://europepmc.org/articles/PMC8629469
http://europepmc.org/articles/PMC8629469
Autor:
Kirtesh R. Patel, Mudit Chowdhary, Akansha Chowdhary, Neilayan Sen, Ruta D. Rao, Parul N. Barry, Melody A. Cobleigh, Dian Wang, Lydia Usha
Publikováno v:
Advances in Radiation Oncology
Advances in Radiation Oncology, Vol 4, Iss 3, Pp 453-457 (2019)
Advances in Radiation Oncology, Vol 4, Iss 3, Pp 453-457 (2019)
Purpose Palbociclib is a selective cyclin-dependent kinase 4/6 inhibitor approved for metastatic ER+/HER2- breast cancer. Preclinical evidence suggests a possible synergistic effect of palbociclib when combined with radiation therapy (RT); however, t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9686a5ebcacf6e8a3911f515451aa987
http://europepmc.org/articles/PMC6639750
http://europepmc.org/articles/PMC6639750
Autor:
Mark T. Uhlik, Jamie Lowe, Maysa M. Abu-Khalaf, Jeremy R. Graff, Paulette Mattson, K Breuer, Michele Gargano, Alison Stopeck, Virginia F. Borges, Ruta D. Rao, Bruno Osterwalder, Joanna Cox, Nandita Bose, Bartosz Chmielowski, Steven J. O'Day, Michael Chisamore
Publikováno v:
Cancer Research. 79:P2-09
Background: CPI monotherapy provides substantial clinical benefit to patients (pts) in multiple cancers, yet response rates are limited (˜15-30%) and fails to benefit the majority. In these pts there is limited or no ongoing T cell-based immune resp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3927f5701ef63e31841145439c2b270d
https://doi.org/10.1158/1538-7445.sabcs18-p2-09-08
https://doi.org/10.1158/1538-7445.sabcs18-p2-09-08
Autor:
Akansha Chowdhary, Mudit Chowdhary, Ruta D. Rao, Melody A. Cobleigh, Neilayan Sen, Demin Wang, Lydia Usha, Parul N. Barry, Kirtesh R. Patel
Publikováno v:
Cancer Research. 79:PD8-12
Purpose: Palbociclib is a selective CDK4/6 inhibitor approved for the treatment of metastatic ER+/HER2- breast cancer. Inhibition of CDK4/6 prevents cell cycle progression from G1 to the more radioresistant S phase, raising the possibility of an enha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::69d8a772c8c1e21d7a77b97d18e69490
https://doi.org/10.1158/1538-7445.sabcs18-pd8-12
https://doi.org/10.1158/1538-7445.sabcs18-pd8-12
Autor:
Emilie C. Robinson, MD, Vicky Kang, BS, Alison Cesarz, BA, Andrea Madrigrano, MD, Katherine A. Kopkash, MD, Gene R. Solmos, MD, Melody A. Cobleigh, MD, Ruta D. Rao, MD, Anuja K. Antony, MD, MPH
Publikováno v:
Plastic and Reconstructive Surgery, Global Open, Vol 5, Iss 9S, Pp 109-109 (2017)
Externí odkaz:
https://doaj.org/article/3b49ea50ceb24cd9b11f9868079d2035
Autor:
Emily J. Gallagher, Heather Moore, Mario E. Lacouture, Susan Faye Dent, Azeez Farooki, Marcus D. Goncalves, Claudine Isaacs, Abigail Johnston, Dejan Juric, Zoe Quandt, Laura Spring, Brian Berman, Melanie Decker, Gabriel N. Hortobagyi, Benjamin Kaffenberger, Bernice Y. Kwong, Timothy J. Pluard, Ruta D. Rao, Lee S. Schwartzberg, Michael S. Broder
Publikováno v:
Journal of Clinical Oncology. 40:422-422
422 Background: ALP is a PI3Kα inhibitor and degrader approved with fulvestrant for the treatment (tx) of patients (pts) with PIK3CA-mutated, HR+, HER2– ABC. Hyperglycemia (HG) and rash are expected adverse events with ALP tx and remain a challeng
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e96da804cc5376f232faff4f6d5eed65
https://doi.org/10.1200/jco.2022.40.28_suppl.422
https://doi.org/10.1200/jco.2022.40.28_suppl.422